Back to News
Market Impact: 0.2
Calithera Biosciences Consensus Price Target Raised 60% to $8.16
Source: Nasdaq
Analyst EstimatesAnalyst InsightsHealthcare & Biotech
The average one-year analyst price target for Calithera Biosciences was revised up 60.00% to $8.16 per share as of January 9, 2023, from $5.10 on December 22, 2022. The figures represent aggregate analyst targets; the article provides no further context or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- Reliance’s Record $19 Billion Surge Lifts Nifty, Keeps India Bulls in the Game
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- Apple reports after the bell. Options traders expect a big move
- Mizuho lowers Lumentum stock price target on Marvell acquisition
- Why is Apple stock falling afterhours today?